A detailed history of New York State Common Retirement Fund transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 132,521 shares of XENE stock, worth $5.16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
132,521
Previous 150,840 12.14%
Holding current value
$5.16 Million
Previous $5.88 Million 11.29%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$36.12 - $43.96 $661,682 - $805,303
-18,319 Reduced 12.14%
132,521 $5.22 Million
Q2 2024

Jul 31, 2024

SELL
$36.25 - $43.75 $1.52 Million - $1.83 Million
-41,912 Reduced 21.74%
150,840 $5.88 Million
Q1 2024

May 07, 2024

BUY
$42.66 - $50.04 $104,090 - $122,097
2,440 Added 1.28%
192,752 $8.3 Million
Q4 2023

Feb 01, 2024

BUY
$28.7 - $46.46 $163,016 - $263,892
5,680 Added 3.08%
190,312 $8.77 Million
Q3 2023

Nov 07, 2023

BUY
$34.16 - $39.73 $34 - $39
1 Added 0.0%
184,632 $6.31 Million
Q2 2023

Aug 07, 2023

BUY
$34.84 - $43.54 $5.75 Million - $7.18 Million
164,952 Added 838.21%
184,631 $7.11 Million
Q1 2023

May 02, 2023

BUY
$33.46 - $40.35 $101,350 - $122,220
3,029 Added 18.19%
19,679 $704,000
Q4 2022

Jan 30, 2023

BUY
$33.06 - $39.43 $21,489 - $25,629
650 Added 4.06%
16,650 $657,000
Q2 2022

Aug 04, 2022

BUY
$25.44 - $35.16 $114,480 - $158,219
4,500 Added 39.13%
16,000 $487,000
Q1 2022

May 05, 2022

BUY
$25.09 - $33.13 $85,306 - $112,642
3,400 Added 41.98%
11,500 $352,000
Q4 2021

Feb 02, 2022

BUY
$15.6 - $35.4 $126,360 - $286,740
8,100 New
8,100 $253,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.